| Literature DB >> 33980935 |
Muhdin Aliye1, Aman Dekebo1, Hailemichael Tesso1, Teshome Abdo1, Rajalakshmanan Eswaramoorthy1, Yadessa Melaku2.
Abstract
Ocimum cufodontii ((Lanza) A.J.Paton) has been traditionally used in Ethiopia against bacteria. The extracts of the leaves and roots of O. cufodontii after silica gel column chromatography furnished compounds 1-5, compounds 3 and 4 are new natural products. The oil from the hydro-distillation of the leaves, after analyzed with GC-MS, has led to the identification of β-caryophyllene as a principal component, suggesting the essential oil as medicine and spices to enhance the taste of food. The constituents of O. cufodontii were assessed for their antibacterial activity against E. coli, K. pneumonia, S. typhymurium and S. aureus. The best activity was displayed against S. aureus by the hexane extract of the roots, compound 4, and the essential oil with an inhibition zone of 17, 15, and 19 mm, respectively. Molecular docking analysis revealed that compound 1 has better docking efficiency and forms hydrophobic interactions with five amino acids (ARG192, PHE196, GLU185, GLU193, and LYS189). This suggests that the compounds may act as potential inhibitors of DNA gyrase. The constituents were also assessed for their antioxidant activities using DPPH, ferric thicyanate and ferric reducing power assay. The hexane extracts of the roots inhibited the DPPH radical and peroxide formation by 90.5 and 83%, respectively, suggesting the potential of the extract as an antioxidant. Furthermore, the hexane extract of the roots of O. cufodontii exhibited the maximum reducing power compared with the EtOAc and methanol extracts. Hence, the activity displayed herein indicated as the plant has great potential as a remedy for diseases caused by bacteria and radicals.Entities:
Year: 2021 PMID: 33980935 PMCID: PMC8115310 DOI: 10.1038/s41598-021-89557-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Structures of compounds 1–5 drawn by ChemDraw Pro 16.0 Suite (PerkinElmer, USA).
1H (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) data of compounds 3.
| No | ||
|---|---|---|
| 6a | 2. 3 (3H, | 19.7 |
| 2 | – | 147.0 |
| 3 | 7.04 (1H, | 128.5 |
| 4 | 7.35 (1H, | 137.0 |
| 5 | – | 128.5 |
| 6 | – | 144.7 |
| 1′ | – | 181.2 |
| 2′ | – | 134.9 |
| 3′ | 7.04 (1H, | 140.1 |
| 4′ | – | 182.3 |
| 5′ | 2.70 (1H, | 40.7 |
| 6′ | 1.08 (3H, | 21.4 |
| 7′ | 1.08 (3H, | 21.4 |
| 1″ | 3.19 (2H, | 24.9 |
| 2″ | 2.67 (2H,t) | 38.5 |
| 3″ | – | 213.6 |
| 4″ | 2.98 (1H, | 26.9 |
| 5″ | 1.13 , 6H, | 18.2 |
| 6″ | 1.13 , 6H, | 19.7 |
δ in ppm and J in Hz.
1H (CDCl3, 400 MHz) and 13C NMR (CDCl3, 100 MHz) data of compounds 4.
| No | 1H-NMR data of compound 4 | 13C-NMR data of compound 4 |
|---|---|---|
| 2 | – | 140.5 |
| 2a | 2.40 (3 H, | 17.8 |
| 3 | 2.90 (1 H, | 55.7 |
| 4 | 7.21 (1H, | 141.2 |
| 5 | 7.04 (1H, | 130.8 |
| 6 | – | 137.9 |
| 7 | 7.08 (1H, | 127.6 |
| 8 | – | 138.3 |
| 8a | – | 129.1 |
| 1′ | 1.40 (2 H, | 22.0 |
| 2′ | 1.98 (2 H, | 40.3 |
| 3′ | – | 210.5 |
| 4′ | 1.25 (1H, | 27.3 |
| 4′a | 1.21 (3H, | 18.9 |
| 4′b | 1.25 (3H, | 18.2 |
| 1″ | 3.00 (2 H, | 29.7 |
| 2″ | – | 203.5 |
| 3″ | – | 81.9 |
| 3″a | 1.04 (3H, | 21.4 |
| 3″b | 0.87 (3H, | 21.5 |
Inhibition zone (in mm) displayed by constituents of the leaves and roots of O. cufodontii at dose of 50 µg/mL.
| Samples | ||||
|---|---|---|---|---|
| HLE | 12.01 (0.20) | 8.00 (0.10) | 6.00 (0.30) | 7.02 (0.10) |
| EALE | 8.00 (0.10) | 6.02 (0.09) | 8.01 (0.09) | 6.00 (0.10) |
| MLE | 8.02 (0.10) | 6.01 (0.19) | 6.02 (0.10) | 6.00 (0.30) |
| HRE | 17.09 (0.30) | 8.01 (0.10) | 7.02 (0.10) | 9.03 (0.09) |
| EARE | 13.00 (0.20) | 6.01 (0.30) | 8.03 (0.08) | 10.01 (0.10) |
| MRE | 15.04 (0.10) | 6.02 (0.30) | 6.03 (0.10) | 6.01 (0.20) |
| EO | 19.04 (0.10) | 6.01 (0.20) | 8.03 (0.50) | 8.00 (0.10) |
| 1 | 12.02 (0.20) | 9.02 (0.30) | 8.03 (0.10) | 10.03 (0.30) |
| 3 | 14.01 (0.30) | 10.02 (0.20) | 7.01 (0.10) | 9.00 (0.10) |
| 4 | 15.02 (0.10) | 11.01 (0.30) | 9.02 (0.40) | 13.03 (0.10) |
| DMSO | 0 | 0 | 0 | 0 |
| Ciprofloxacin | 19.30 (0.10) | 19.01 (0.67) | 22.00 (0.10) | 21.50 (0.30) |
Samples were analyzed in triplicates and expressed as m ± SD.
HLE hexane leaves extract, EALE EtOAc leaves extract, MLE MeOH leaves extract, HRE hexane root extract, ERE EtOAc root extract, MRE MeOH root extract, EO Essential oil.
DPPH radical scavenging and lipid peroxidation inhibitory activities of extracts and constituents of the roots and leaves of O. cufodontii.
| Samples | %DPPH inhibition at | Anti-lipid peroxidation | ||||
|---|---|---|---|---|---|---|
| 200 (µg/mL) | 100 (µg/mL) | 50 (µg/mL) | 25 (µg/mL) | |||
| HLE | 65.02 (0.04) | 57.90 (0.20) | 52.81 (0.03) | 51.72 (0.09) | 70.01 (0.08) | |
| EALE | 68.32 (0.01) | 53.21 (0.09) | 50.73 (0.07) | 48.50 (0.11) | 52.02 (0.12) | |
| HRE | 90.50 (0.03) | 85.01 (0.05) | 61.22 (0.08) | 50.90 (0.08) | 83.02 (0.01) | |
| EARE | 52.44 (0.01) | 49.23 (0.01) | 48.81 (0.02) | 45.92 (0.20) | 57.01 (0.70) | |
| 1 | 32.30 (0.03) | 28.52 (0.06) | 24.00 (0.10) | 19.21 (0.09) | 22.01 (0.19) | |
| 3 | 39.22 (0.31) | 35.81 (0.90) | 28.22 (0.05) | 16.80 (0.40) | 76.02 (0.80) | |
| 4 | 37.90 (0.27) | 32.70 (0.50) | 26.90 (0.10) | 22.82 (0.20) | 69.01 (0.10) | |
| Ascorbic acid | 93.02 (0.02) | 80.02 (0.04) | 60.02 (0.05) | 50.09 (0.02) | 87.08 (0.02) | |
| Quercetin | 89.01 (0.06) | 73.00 (0.10) | 64.03 (0.21) | 64.01 (0.08) | 85.02 (0.07) | |
HLE hexane leaves extract, EALE EtOAc leaves extract, HRE hexane root extract, EARE EtOAc root extract; Samples were reported as mean ± SEM; Ascorbic acid and quercetin used as positive control were measured at 100, 50, 25 and 12 µg/mL.
Ferric-reducing potential of extracts and isolated compounds of O. cufodontii.
| Samples | mmol Fe(II)/mg of samples |
|---|---|
| HLE | 0.090 (0.004) |
| EALE | 0.087 (0.003) |
| HRE | 1.120 (0.007) |
| EARE | 0.900 (0.006) |
| 1 | 0.050 (0.009) |
| 3 | 0.070 (0.009) |
| 4 | 0.060 (0.001) |
| Ascorbic acid | 1.250 (0.002) |
Samples were measured in triplicates and expressed as M ± SD; Ascorbic acid was used as positive control.
Molecular docking value of compounds isolated from root extracts of O. cufodontii.
| Compounds | Affinity (kcal/mol) | H-bond | Residual interactions | |
|---|---|---|---|---|
| Hydrophobic/Pi-Cation | Van dar Waals | |||
| − 6.3 | Arg-76 | Ile-78 | Asp-73, Glu-50, Ile-94, Asp-49, Ieu-98, Val-120 | |
| − 6.1 | – | Ile-78, Ile-94, Glu-50 | Asp-73, Arg-76, Asn-46, Gly-77, Thr-165, Asp-49, | |
| − 6.9 | Asn-46, Arg-76 | Ile-78, Glu-50 | Asp-43, Ala-47, Gly-77, Pro-79, Val-43, Arg-136, Val-167, Thr-165 | |
| − 6.6 | Asn-46 | Glu-50, Ile-78 | Asp-73, Asp-49, Ala-47, Gly-77, Pro-79, Ile-94, Arg-76, Val-43, Thr-165, Val-167 | |
| − 6.6 | Asp-73 | Arg-76 | Asn-46, Ala-47, Glu-50, gly-77, Ile-78, Pro-79, Thr-165 | |
| − 6.9 | Asp-73, Asn-46, Arg-76 | Ile-78, Ile-94, Glu-50, Gly-77 | Ala-47, Pro-79, Thr-165 | |
Figure 2The 2D and 3D intermolecular contact between compound 1 and DNA gyrase B (PDB ID: 6F86). Chemical structures were drawn by ChemDraw Pro 16.0 Suite (PerkinElmer, USA) and analyzed by the Discovery studio visualizer (BIOVIA Discovery studio 2020 Client).
Figure 3The 2D and 3D intermolecular contact between compound 2 and DNA gyrase B (PDB ID: 6F86). Chemical structures were drawn by ChemDraw Pro 16.0 Suite (PerkinElmer, USA) and analyzed by the Discovery studio visualizer (BIOVIA Discovery studio 2020 Client).
Figure 4The 2D and 3D intermolecular contact between compound 4 and DNA gyrase B (PDB ID: 6F86). Chemical structures were drawn by ChemDraw Pro 16.0 Suite (PerkinElmer, USA) and analyzed by the Discovery studio visualizer (BIOVIA Discovery studio 2020 Client).
Figure 5The 2D and 3D intermolecular contact between compound 5 and DNA gyrase B (PDB ID: 6F86). Chemical structures were drawn by ChemDraw Pro 16.0 Suite (PerkinElmer, USA) and analyzed by the Discovery studio visualizer (BIOVIA Discovery studio 2020 Client).
Figure 6The 2D and 3D intermolecular contact between ciprofloxacin and DNA gyrase B (PDB ID: 6F86). Chemical structures were drawn by ChemDraw Pro 16.0 Suite (PerkinElmer, USA) and analyzed by the Discovery studio visualizer (BIOVIA Discovery studio 2020 Client).